

| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |



INEQUALITIES IN DISABILITY-FREE AND DISABLING MULTIMORBID LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES

Anastasia Lam^{1,2}, Katherine Keenan², Genevieve Cezard³, Hill Kulu², Mikko Myrskylä^{1,4}

- ¹ Max Planck Institute for Demographic Research
- ² School of Geography and Sustainable Development, University of St Andrews
- ³ Department of Public Health and Primary Care, University of Cambridge
- ⁴ Center for Social Data Science and Population Research Unit, University of Helsinki

CEPAR International Conference 2023, 3-5 July 2023



| 0 0 0 0 0 0 0 0 | | | | - | I | | | | | Ι | | | 4 | | |
|-----------------|------------|-----|-----|-----|-----|---|-----|---|---|-----|---|---|-----|---|---|
| 0 0 0 0 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| •••• AGF | NDA | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | Background | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | Methods | | | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | | | | |
| 0 0 0 0 | Deculto | | | | | | | | | | | | | | |
| | Results | | | | | | | | | | | | o o | 0 | 0 |
| | | | | | | | | | | | | | o o | 0 | 0 |
| | Discussion | | | | | | | | | | | | o o | 0 | 0 |
| | DISCUSSION | | | | | | | | | | | | o o | 0 | 0 |
| | | | | | | | | | | | | | o o | 0 | 0 |
| | | | | | | | | | | | | | o o | 0 | 0 |
| | | | | | | | | | | | | | o o | 0 | 0 |
| | | | | | | | | | | | | | o o | 0 | 0 |
| | | o o | o o | 0 0 | 0 0 | 0 | o o | 0 | 0 | 0 0 | 0 | 0 | o o | 0 | 0 |
| | | 0 0 | 0 0 | 0 0 | 0 0 | 0 | 0 0 | 0 | 0 | 0 0 | 0 | 0 | 0 0 | 0 | 0 |



| 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 AGENDA 0 0 0 0 0 0 0 0 0 0 | | |
|---|--|---|------------------------------------|
| | Background | Multimorbidity | |
| o o o o o o o o o | Methods | Multimorbid life expectancy Disability | |
| 0 0 0 0 | Results | Country context | 0 0 0 0 0 0 0 0 |
| | Discussion | Research questions | |
| | | | 0 0 0 0 |
| | | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 |



WHAT WE DO AND DON'T KNOW ABOUT MULTIMORBIDITY

- Multimorbidity is usually defined as 2+ co-occurring chronic diseases
- It is common and well-studied in high-income countries
 - But there is a rising prevalence and lack of research in low- and middle-income countries, where almost 80% of NCD-related deaths occur and populations are rapidly ageing (WHO 2022)
 - Some LMICs also have different disease constellations compared to HICs, e.g., tuberculosis, HIV/AIDS, and malnutrition
- Most studies describe multimorbidity prevalence or disease clusters at single time-points
 - Sparse evidence on multimorbidity longitudinally (Cezard et al. 2021)
 - Few studies on time spent living with multimorbidity (or chronic morbidities) (*Tetzlaff et al. 2017, Botes et al. 2018, Kingston et al. 2018, Chan et al. 2019, Payne 2022*)



WHAT IS MULTIMORBID LIFE EXPECTANCY?

 Multimorbid life expectancy (MMLE) describes the years someone is expected to live with multimorbidity





WHY DISABILITY AND MULTIMORBIDITY?

- Multimorbidity is associated with increased disability
 - The amount of disability seems to depend on disease counts and multimorbidity patterns (*Jindai 2016*, *Quinones 2016*, *Sheridan 2019*)
- Less is known about the burden of multimorbidity in terms of disability-adjusted life years (DALYs) or years lost to disability (YLD) (Academy of Medical Sciences 2018)
- In this study, I use disability as a proxy to determine multimorbidity severity/progression



WHY COMPARE COSTA RICA, MEXICO, AND THE UNITED STATES?

- Data availability
- Geographic proximity, varying economic, health, and educational system structures
- Costa Rica and Mexico have similar GDP, but Costa Rica has higher life expectancy
- In contrast, the US has much higher GDP and spends a greater percentage of their GDP on health (in 2018, 17% vs 7% in Costa Rica and 5% in Mexico), but has lower life expectancy than Costa Rica (World Bank 2022)
- Many more historical, cultural, structural differences...



| | 0 0 0 0 C | | |
|----------------|-----------|---|---|
| 0 0 0 | 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 | |
| 0 0 0 | | | |
| | | | |
| 0 0 0 | 0 | | |
| 0 0 0 | 0 | | |
| 0 0 0 | 0 | | |
| 0 0 0 | 0 | | |
| o o o | 0 | | |
| o o o | • | | |
| o o o | 0 | | |
| o o o | 0 | INFOLIAL ITIES IN | |
| 0 0 0 | 0 | | |
| 0 0 0 | 0 | DISABILITY-FREE AND DISABIING MULTIMORBID | |
| | | | |
| 0 0 0 | 0 | | |
| 0 0 0 | 0 | LIFE EXPECTANCY IN | |
| 0 0 0 0 0 0 | o 0 | | |
| 0 0 0 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0 |
| 0 0 0 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | o o o o |
| 0 0 0 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0 0 0 0 0 |
| 0 0 0 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0 0 0 0 0 |
| 0 0 0 0 0 0 | • | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0 0 0 0 0 0 0 |
| 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0< |
| 0 0 0 | • | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0< |
| 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0< |
| 0 0 0 0 0 0 | • | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0< |
| 0 0 0 | 0 | LIFE EXPECTANCY IN COSTA RICA, MEXICO, AND THE UNITED STATES | 0 0< |















| 0 | | |
|---|---------------------------------------|---|
| 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | |
| 0 0 0 | | |
| | | |
| | | |
| 0 0 0 0 | | |
| 0 0 0 0 | | |
| | | |
| Background | Data sources | |
| Dackground | Data sources | |
| 0 0 0 0 | | |
| Notbodo | Definitione | |
| · · · · · Methods | Definitions | |
| 0 0 0 | | |
| 0 0 0 0 | | |
| Results | State space | 0 |
| | | 0 |
| | | 0 |
| Discussion | Statistical analysis | ~ |
| | | 0 |
| | | 0 |
| | | 0 |
| | 0 0 0 | 0 |
| | 0 0 0 | 0 |
| | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 0 |
| | | 0 |



DATA SOURCES





DEFINITIONS

| Multimorbidity | Disability | Education |
|--|--|---|
| Have you ever been told you had at least 2 of the following diseases: Arthritis Cancer Diabetes Hypertension* Heart problems Respiratory problems | Reported some difficulty with at least 1 of the following activities of daily living: Bathing Eating Getting in/out of bed Walking | Highest level of reported educational attainment: Primary school or less Secondary school Post-secondary school |



STATE SPACE





STATISTICAL ANALYSIS





0 0 ο ο ο 0 0 0 0

0 0 0 0

0

0 0 0

0

0 0

ο 0 0 ο 0 0

0 0

0 0

0 0

0 0 0 0

0 0

0 0

0 0

0 0 0 0

0 0

0 0

0 0 0 0

0 0 0 0

0 0 0 0 0

| o o | |
|---|--|
| ••••• AGENDA | |
| | |
| Background | Descriptive results |
| Methods | Disease prevalence and combinations |
| Results | Total, disability-free, and disabling MMLE |
| Discussion | Educational differences |
| | |
| | |



DESCRIPTIVE STATISTICS

| | Costa | Rica | Mex | ico | United States | | | | | |
|--------------------------------|-------------------|---------------------|-------------------|---------------------|-------------------|----------------------|--|--|--|--|
| | Male (N=1,200) | Female (N=1,426) | Male (N=4,994) | Female (N=6,214) | Male (N=9,599) | Female (N=12,746) | | | | |
| Mean age in years (SD) | 76.9 (10.3) | 76.9 (10.2) | 70.2 (7.9) | 69.9 (8.1) | 68.6 (8.3) | 69.2 (9.2) | | | | |
| Education level | | | | | | | | | | |
| Primary school or less | 1040 (86.7%) | 1246 (87.5%) | 3691 (73.9%) | 4868 (78.3%) | 680 (7.1%) | 776 (6.1%) | | | | |
| Secondary school | 93 (7.7%) | 107 (7.5%) | 784 (15.7%) | 1075 (17.3%) | 4540 (47.3%) | 6969 (54.7%) | | | | |
| Post-secondary school | 67 (5.6%) | 71 (5.0%) | 519 (10.4%) | 271 (4.5%) | 4379 (45.6%) | 5001 (39.2%) | | | | |
| Initial 'from' state | | | | | | | | | | |
| 0 disease | 438 (36.5%) | 330 (23.2%) | 1607 (32.2%) | 1048 (16.9%) | 1503 (15.7%) | 1625 (12.7%) | | | | |
| 1 disease | 436 (36.3%) | 525 (36.9%) | 1662 (33.3%) | 1973 (31.8%) | 2457 (25.6%) | 3259 (25.6%) | | | | |
| Disability-free multimorbidity | 237 (19.8%) | 413 (29.0%) | 1337 (26.8%) | 2333 (37.5%) | 4614 (48.1%) | 5871 (46.1%) | | | | |
| Disabling multimorbidity | 89 (7.4%) | 156 (11.0%) | 388 (7.8%) | 860 (13.8%) | 1025 (10.7%) | 1991 (15.6%) | | | | |

STATE EXPECTANCIES BY GENDER AND COUNTRY



Years of remaining life expectancy from age 60

STATE EXPECTANCIES BY GENDER, COUNTRY & EDUCATION





| | | | ** | | | | <u> </u> | | Lalo | 1 | | |
|---------|-----------------------------|-------------|---------|-----|-------|-----|----------|-----|------|-----|----------|----|
| 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | • | 1 | | | | | | | | |
| o o o o | 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | | | | | | | | | | | |
| o o o o | 0 0 0 0 0 0 0 0 0 0 0 0 0 | | | | | | | | | | | |
| o o o o | | | | | | | | | | | | |
| o o o o | AGENDA | | | | | | | | | | | |
| o o o o | AOLINDA | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | |
| | Background | Summary | | | | | | | | | | |
| | Baokgroana | Guinnary | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | |
| 0 0 0 0 | Methods | Limitations | | | | | | | | | | |
| 0 0 0 0 | Mictiliou3 | Limitations | | | | | | | | | | |
| 0 0 0 0 | | | | | | | | | | | | |
| 0 0 0 0 | Poculte | Conclusions | | | | | | | | | | |
| | Results | Conclusions | | | | | | | | • • | 0 | 0 |
| | | | | | | | | | | • • | 0 | 0 |
| | Discussion | | | | | | | | | • • | 0 | 0 |
| | DISCUSSION | | | | | | | | | • • | 0 | 0 |
| | | | | | | | | | | • • | o | 0 |
| | | | | | | | | | | 0 0 | • | 0 |
| | | | | | | | | | | 0 0 | 0 | 0 |
| | | | | | | | | | | 0 0 | o | 0 |
| | | 0 | 0 0 0 0 | 0 0 | 0 0 0 | 0 0 | 0 0 | 0 0 | 0 | 0 0 | 0 | 0 |
| | | 0 | 0 0 0 0 | 0 0 | 0 0 0 | 0 | 0 0 | 0 0 | 0 | 0 0 | 0 | °. |
| | | • | | | | | | | | | - | - |



SUMMARY

- Regardless of gender or education, people in Costa Rica lived longer, healthier lives than people in Mexico or the United States
- Greatest inequalities observed for disability-free multimorbidity, with people in the United States having almost twice the disability-free MMLE than people in Costa Rica
- Women had higher MMLE and LE than men
- Positive education gradient for disability-free MMLE and negative education gradient for disabling MMLE in the United States



LIMITATIONS

- Small samples and limited number of transitions in CRELES and MHAS
 - Wide confidence intervals
- Limited to 7 chronic conditions
 - Overestimate people without disease, underestimate people with disease



CONCLUSIONS

- While we identified gender and educational inequalities, the magnitude of these inequalities differed across all countries, highlighting the fact that contextual factors are likely major contributors to MMLE.
 - E.g., Access, quality, and utilization of healthcare; differences in health behaviors; disease screening, diagnosis, and treatment protocols
- MMLE can act as a complementary measure of population health alongside healthadjusted or disability-free life expectancy to aid healthcare providers with disease management and prevention
 - The concept of MMLE can also be extended further to incorporate e.g., instrumental activities of daily living, cognitive function



0 0 THANK YOU FOR 0 0 0 0 **YOUR ATTENTION!** 0

0 0 0 0

Anastasia Lam

lam@demogr.mpg.de





0 0 0 0 0 0 0

0

0



0 0